The company has not filed an annual or quarterly report since its Q2 FY2021 10-Q, filed Aug 16, 2021. Its latest SEC filing is a SC 13G/A from Feb 14, 2022.
10-Q for Q2 FY2021, filed Aug 16, 2021
The sections below describe the company as of the FY2020 annual report.
Sells generic skin, injectable and eye medicines through drug wholesalers and pharmacies, and develops and manufactures products for pharmaceutical, over-the-counter and cosmetic companies.
10-K for FY2020, filed May 4, 2021We currently market and sell generic topical and generic and branded generic injectable pharmaceutical products in the United States and…View ↗
We develop, manufacture, fill and package topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well…View ↗
We sell, distribute and market our prescription drug products to national chain drug stores and drug wholesalers and distributors and group…View ↗
Most revenue comes from sales of its own medicines; customers pay when products are delivered. It also makes products for pharmaceutical, over-the-counter and cosmetic customers, with manufacturing payments as milestones are reached and development payments when each agreed phase is completed.
10-K for FY2020, filed May 4, 2021Years ended December 31, 2020 2019 Company product sales $ 43,604 $ 64,291 Contract manufacturing sales 1,157 1,362 Research and…View ↗
Revenue from Company product sales is recognized upon transfer of control of a product to a customer at a point in time, generally as the…View ↗
The Company recognizes revenue for contract manufacturing sales over-time, as milestones are achieved. Shipments are made in accordance…View ↗
The Company establishes agreed upon product development agreements with its customers to perform product development services. Revenues are…View ↗
$45.3M
10-K for FY2020, filed May 4, 2021
$45.3M ↗
It sells prescription medicines to wholesalers, distributors, national chain drug stores and purchasing groups. Pharmaceutical companies and over-the-counter and cosmetic marketers use its product development and manufacturing services.
10-K for FY2020, filed May 4, 2021
No. It lost $122M in .
10-Q for Q2 FY2021, filed Aug 16, 2021
−$12.9MView ↗
8-K, filed Oct 15, 2021
On October 14, 2021, Teligent, Inc. (the “Company”) and certain of its affiliates (collectively, the “Debtors”) filed a voluntary petition…View ↗
8-K, filed Sep 27, 2021
On September 21, 2021, Ernest R. De Paolantonio, the Chief Financial Officer of Teligent, Inc. (the “Company”), notified the Company of his…View ↗
Shrank. Revenue fell 79% in 4 years, from $217.6M in to $45.3M in , about 32% a year.
Contract-services emphasis
The latest report puts added emphasis on private-label and contract development and manufacturing, while the older report expected contract-services revenue to decline as more resources went to internal products.
10-K for FY2017, filed Mar 19, 2018 10-K for FY2020, filed May 4, 2021We believe that our quality contract manufacturing and development business provides a consistent and reliable source of products and…View ↗
Since 2010, the primary focus of our strategy has been on the growth of our own generic prescription pharmaceutical business particularly…View ↗
Loading...
